Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals Inc.
WKN: 881535 / Symbol: REGN / Name: Regeneron / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
972,80 €
-0,53 %
Buy Regeneron Pharmaceuticals Inc.
Buy Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at EF Hutton Acquisition Co. I from $853.00 to $862.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at SVB Securities from a "market perform" rating to an "outperform" rating. They now have a $976.00 price target on the stock, up previously from $834.00.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Bank of America Co. from $605.00 to $650.00. They now have an "underperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Erste Group Bank AG.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Morgan Stanley from $897.00 to $912.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Barclays PLC from $888.00 to $900.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,045.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "buy" rating. They now have a $992.00 price target on the stock, up previously from $720.00.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Argus from $825.00 to $920.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Morgan Stanley from $912.00 to $915.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $915.00 to $914.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,045.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Jefferies Financial Group Inc. from $935.00 to $937.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Neueste Beiträge
Tigress_Financial in Discuss Wal-Mart Stores Inc., Walmart Inc.